DAB2IP and neoplasm: Notably, its mutation rate in cancers is relatively limited, and its loss-of-function is most frequently dependent on transcriptional silencing or post-transcriptional inactivation mechanisms; this makes DAB2IP a strong candidate for the development of therapeutics aimed to restore its tumor-suppressive function.